Revalia Bio
Revalia Bio operates a five-layer 'Human Data Stack' platform that uses donated human organs and AI to deliver predictive pre-clinical drug safety and efficacy insights for pharmaceutical and biotechnology clients. Founded in 2022 by Yale scientists and headquartered in New Haven, Connecticut.
- Company typePrivate
- Founded2022
- HeadquartersNew Haven, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Revalia Bio does
Revalia Bio is a private, venture-backed pre-clinical research company founded in 2022 by Yale scientists Greg Tietjen, Jenna DiRito, and Kourosh Saeb-Parsy, headquartered in New Haven, Connecticut. The company operates a five-layer 'Human Data Stack' platform that transforms donated human organs and tissues (sourced through partnerships with organ procurement organizations) into multi-modal biological datasets, then applies Revalia AI — a foundational model layer — to generate decision-ready insights for drug and device development. Predictive outputs cover safety signals, dose selection, target selection, patient selection, PK/PD profiles, biodistribution, mechanism of action, and optimized delivery. The company's 2025 launch of a purpose-built Organ ICU facility in New Haven and integration of Draper's PREDICT96 microphysiological system operationalize this pipeline at scale.
Revalia Bio serves pharmaceutical and biotechnology companies as primary customers, with regulatory bodies and healthcare providers identified as secondary segments. The go-to-market is enterprise field sales with a consultation-based, 'Book a Call' engagement model and quote-based pricing rather than self-serve or marketplace distribution. Revenue is generated through professional services (human organ research projects) and what the company describes as subscription/recurring AI-powered drug development insights, though specific pricing is not publicly disclosed. The company reports two signed top pharmaceutical customers and first revenue from human organ research services in 2023.
Capital structure is private with no subsidiaries or parent entities. Equity funding totals approximately $19.5 million across an initial 2023 round ($5M from Connecticut Innovations, Leva Capital, Overmatch Ventures) and a 2024-2025 seed round ($14.5M led by America's Frontier Fund and Sierra Ventures, with National Kidney Foundation and Connecticut Innovations). In December 2025, the company was awarded up to $26.7 million under the ARPA-H CATALYST program, in partnership with Draper, the Krishnaswamy Lab at Yale, and LifeShare Network, to develop in silico models of human physiology. The board includes America's Frontier Fund's Brian Wilcove, deep-tech investor Ben Yu, former Fed Vice Chair and TIAA CEO Roger Ferguson, and Pamir Ventures' Milad Alucozai.
Revalia Bio firmographics
Firmographics- Name
- Revalia Bio
- Legal name
- Revalia Bio, Inc.
- Website
- https://revaliabio.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Revalia Bio operates a five-layer 'Human Data Stack' platform that uses donated human organs and AI to deliver predictive pre-clinical drug safety and efficacy insights for pharmaceutical and biotechnology clients. Founded in 2022 by Yale scientists and headquartered in New Haven, Connecticut.
- Ownership category
- akta.pro rank
Revalia Bio industry classification
Industry- Product category
- Preclinical Drug Development Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD)
- akta.pro secondary industries
- In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where Revalia Bio is headquartered
LocationHeadquarters
- HQ city
- New Haven
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Revalia Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Revenue model
- Human Organ Research Services: Revenue generated from providing human organ research services to pharmaceutical and biotech companies. The company provides early predictive insights for drug development through human data trials.
- AI-Powered Drug Development Insights: Providing decision-ready insights for drug and device development based on human biology data, potentially through subscriptions or project-based engagements.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Revalia Bio product offering
Product offeringCore offering
Revalia Bio transforms donated human organs and tissues into high-fidelity biological data using its AI-powered Human Data Stack, delivering 'Human Data Trials' as an alternative to traditional preclinical animal testing. The five-layer platform (Generate, Ingest, Integrate, Interpret, Deliver) and Revalia AI engine produce decision-ready insights across drug safety, dose selection, target selection, patient selection, PK/PD profiles, biodistribution, mechanism of action, and optimized delivery for pharmaceutical and biotechnology customers.
Product overview
Revalia Bio operates as a platform company offering the Human Data Stack, an end-to-end infrastructure consisting of five integrated layers (Generate, Ingest, Integrate, Interpret, and Deliver). The platform transforms donated human organs and tissues into high-fidelity biological data through its proprietary Revalia AI engine and state-of-the-art Organ ICU facility. The core Human Data Trials offering provides early predictive insights for drug development, including safety signals, dose selection, target selection, patient selection, PK/PD profiles, biodistribution profiles, mechanism of action, and optimized delivery predictions. Founded by Yale scientists in 2022, the company has developed partnerships with pharmaceutical companies and is funded through ARPA-H contracts.
Differentiator
Problem solved
Functional benefit
Products and services
- Human Data Stack End-to-end five-layer infrastructure (Generate, Ingest, Integrate, Interpret, Deliver) that converts donated human organs and tissues into multi-modal biological datasets for drug and device development, with AI embedded at every junction.
- Revalia AI Foundational AI/ML engine powering the Human Data Stack, delivering decision-ready insights across drug development including Safety Signals, Dose Selection, Target Selection, Patient Selection, PK/PD Profiles, Biodistribution Profiles, Mechanism of Action, and Optimized Delivery.
- Human Data Trials New category of preclinical testing that uses donated human organs and tissues to provide early, predictive insights for drug development, serving pharmaceutical and biotech customers as an alternative to animal testing and traditional preclinical models.
Quantifiable outcome
- Superior prediction of drug-induced liver injury compared to animal models
Companies that use Revalia Bio
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
Revalia Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
Revalia Bio partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered flagship and core.
- DraperflagshipDraper leads the CATALYST program awarded up to $26.7 million in ARPA-H funding. The partnership develops in silico models of human physiology using a four-layer Human Data Stack integrating patient records, donated organ data, tissue biopsies, and Draper's PREDICT96 microphysiological system to predict drug safety and effectiveness.
- Krishnaswamy Lab at Yale UniversityflagshipYale research lab awarded ARPA-H funding as a key partner in the CATALYST program. The Krishnaswamy Lab contributes computational models using AI and machine learning to develop the Human Data Stack for drug development.
- LifeShare NetworkflagshipPartner in the CATALYST program contributing to the development of in silico models of human physiology for drug development.
- Organ Procurement Organizations (OPOs)corePartnership with leading organ procurement organizations to source donated human organs and tissues for research while ensuring ethical handling and respect for donor gifts.
- Healthcare InstitutionscorePartnership with healthcare partners to ensure every donor gift is handled with highest ethical standards, transparency, and respect throughout its lifecycle.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
Revalia Bio competitors and assessment
Company assessmentBroad incumbents
- Recursion: Recursion combines high-throughput wet-lab biology with AI/ML to drive drug discovery at scale; it competes with Revalia for the same AI-enabled preclinical narrative at large pharma, though with a broader target-discovery franchise.
- Schrödinger: Schrödinger operates a physics-based computational platform for drug discovery and materials, competing for preclinical R&D budgets at large pharma and offering overlapping predictive-modeling capabilities to Revalia AI.
- Insilico Medicine: Insilico Medicine is a more established AI-driven drug discovery platform using generative AI and multi-omics; it competes with Revalia AI for pharma R&D share but is broader in scope and later-stage across target ID through preclinical pipelines.
Direct peers
- TissUse: TissUse develops multi-organ-chip platforms that connect several human organ equivalents on a single chip, directly overlapping with Revalia's multi-organ, microphysiological system strategy for systemic drug safety/efficacy testing.
- Emulate: Emulate is the leading commercial organ-on-chip company whose Organ-Chip platform is the most direct competitor to Revalia's organ-based preclinical offering; both target pharma customers seeking human-relevant preclinical alternatives to animal models.
- Mimetas: Mimetas provides OrganoPlate-based organ-on-chip and disease modeling platforms used by pharma for preclinical testing, positioning it as a direct competitor in the human-relevant in vitro preclinical space.
- CN Bio: CN Bio offers single- and multi-organ microphysiological systems (including PhysioMimix) for drug development, directly competing with Revalia's organ-on-chip + PREDICT96 microphysiological approach for pharma preclinical customers.
- InSilicoTrials: InSilicoTrials runs in silico clinical and preclinical trials using computational models, competing for the same 'replace/supplement animal testing' pharma budget as Revalia's Human Data Trials offering, albeit via simulation rather than donated organs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Revalia Bio social profiles
Digital presenceRevalia Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Revalia Bio leadership team
Management profileNumber of profiles
Profiles13 records
Revalia Bio funding detail
Funding detailFunding overview
Funding rounds3 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Revalia Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Revalia Bio
What does Revalia Bio do?
Revalia Bio transforms donated human organs and tissues into high-fidelity biological data using its AI-powered Human Data Stack, delivering 'Human Data Trials' as an alternative to traditional preclinical animal testing. The five-layer platform (Generate, Ingest, Integrate, Interpret, Deliver) and Revalia AI engine produce decision-ready insights across drug safety, dose selection, target selection, patient selection, PK/PD profiles, biodistribution, mechanism of action, and optimized delivery for pharmaceutical and biotechnology customers.
Is Revalia Bio a public or private company?
Revalia Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Revalia Bio founded?
Revalia Bio was founded in 2022. It employs 11 to 50 people.
Where is Revalia Bio based?
Revalia Bio is headquartered in New Haven, United States, in the North America region.
How does Revalia Bio make money?
Two revenue lines are on record. Human Organ Research Services are the primary driver. The others are AI-Powered Drug Development Insights.
Who are Revalia Bio's main competitors?
Broad incumbents on record are Recursion, Schrödinger and Insilico Medicine. Direct peers are TissUse, Emulate, Mimetas, CN Bio and InSilicoTrials.
Does Revalia Bio have an API?
No public API is recorded for Revalia Bio.
What industry is Revalia Bio in?
Revalia Bio's product category is Preclinical Drug Development Services. Its primary akta.pro industry code is HLAAAGAD, Organoids & Organ-on-Chip (regenerative models), with a secondary code of HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems). Its NAICS code is 541714 and its SIC code is 8071.